ReviewDrugs2019
Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Phase 2, Multicenter Studies of Pegaspargase in Pediatric Patients With Previously Untreated Acute Lymphoblastic Leukemia in Russia: Comparative Study of Liquid and Lyophilized Pegaspargase and Roll-Over Study of Lyophilized Formulation.Journal of pediatric hematology/oncology · 2026Trial
- Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia.JCO global oncology · 2020Trial
- Engineering molecularly imprinted polymers for receptor-specific cancer therapeutics.Nanoscale · 2026Review
- A Multicenter Survival Analysis of Adults Type B-Acute Lymphoblastic Leukemia in Ecuador. A Retrospective Study of the Real World.Cancer medicine · 2026Article
- Molecular Survival Strategies Against Kidney Filtration: Implications for Therapeutic Protein Engineering.Biophysica · 2026Article
- Pancreatitis induced by Peg-aspargase in children: a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS).Leukemia research reports · 2026Article
- Daratumumab-based salvage therapy enables umbilical cord blood transplantation in multiline refractory, elderly T-lymphoblastic lymphoma: a case report.Frontiers in immunology · 2026Article
- Relapse risk and outcome of discontinuing asparaginase in children with acute lymphoblastic leukemia.Annals of hematology · 2025Article
- L-asparaginase: a review of microbial production and protein engineering with translational applications for oncology and food safety.World journal of microbiology & biotechnology · 2025Review
- Enhancing stability of enzymes for industrial applications: molecular insights and emerging approaches.World journal of microbiology & biotechnology · 2025Review
- Biochemical and Biophysical Divergences between TwoBiochemistry · 2025Article
- Pharmacokinetics of Pegaspargase with a Limited Sampling Strategy for Asparaginase Activity Monitoring in Children with Acute Lymphoblastic Leukemia.Pharmaceutics · 2025Article
- Insights on the Role of Sialic Acids in Acute Lymphoblastic Leukemia in Children.International journal of molecular sciences · 2025Review
- BeyondChemical reviews · 2025Review
- Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.Molecular cancer · 2025Review
- Comparison of pegaspargase with concurrent radiationOncology research · 2025Article
- SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy.Drug design, development and therapy · 2025Article
- Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence.Frontiers in oncology · 2025Review
- Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pegaspargase (Oncaspar
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.